%20scale(0.100000,-0.100000)'%20fill='%23000000'%20stroke='none'%3e%3cpath%20d='M588%201715%20c-2%20-2%20-23%20-4%20-48%20-6%20-108%20-7%20-216%20-64%20-304%20-162%20l-56%20-61%200%2096%200%2097%20-32%203%20c-18%202%20-52%201%20-75%20-1%20l-43%20-3%200%20-589%20c0%20-554%201%20-589%2018%20-590%2036%20-2%20124%20-1%20127%203%202%201%205%20156%208%20343%205%20360%207%20386%2036%20471%2063%20178%20244%20284%20406%20236%2069%20-20%20119%20-58%20150%20-114%2041%20-75%2043%20-96%2044%20-575%20l1%20-363%2075%200%2075%200%200%2053%20c0%20215%209%20628%2015%20657%2022%20116%2064%20203%20124%20258%2020%2019%2065%2048%20101%2065%2053%2025%2076%2031%20132%2030%20121%200%20220%20-70%20248%20-173%2019%20-69%2021%20-128%2022%20-515%201%20-198%205%20-365%209%20-370%208%20-11%20119%20-12%20136%20-2%205%204%209%20168%208%20404%20-2%20333%20-5%20411%20-19%20478%20-43%20197%20-167%20313%20-349%20323%20-137%208%20-274%20-47%20-355%20-144%20-18%20-21%20-41%20-48%20-51%20-59%20-10%20-11%20-21%20-30%20-25%20-43%20-7%20-22%20-31%20-26%20-31%20-5%200%205%20-11%2032%20-25%2059%20-36%2071%20-109%20138%20-177%20164%20-55%2020%20-139%2040%20-145%2035z'/%3e%3cpath%20d='M63%20202%20c-38%20-2%20-53%20-7%20-57%20-20%20-6%20-19%200%20-61%2010%20-71%203%20-3%20111%20-6%20240%20-6%20256%200%20254%20-1%20254%2058%200%2015%20-6%2030%20-14%2033%20-16%206%20-352%2011%20-433%206z'/%3e%3cpath%20d='M680%20201%20c-30%20-4%20-37%20-14%20-36%20-49%201%20-17%209%20-31%2024%20-38%2025%20-12%20435%20-12%20465%201%2011%205%2017%2018%2017%2040%200%2022%20-6%2035%20-17%2040%20-19%207%20-409%2013%20-453%206z'/%3e%3cpath%20d='M1360%20202%20c-73%20-5%20-78%20-9%20-74%20-48%202%20-20%206%20-39%209%20-43%2010%20-9%20447%20-9%20473%200%2017%207%2022%2016%2022%2044%200%2021%20-6%2038%20-14%2041%20-15%206%20-356%2011%20-416%206z'/%3e%3c/g%3e%3c/svg%3e)
The FY2025 (Dec) proxy of Moderna names 12 peer companies for pay. Among Moderna and these peers, CEO pay was 3rd highest of 4 and total shareholder return was the lowest of 4.
3rd highest of 4in Moderna and its pay peers, FY2025 (Dec) by CEO pay:
$7.3M$32.1M
4th highest of 4in Moderna and its pay peers, FY2025 (Dec) by total shareholder return:
$28$160
Pay peer group, FY2025 (Dec) proxy
| Incyte | ||
| Bristol Myers Squibb | ||
| Regeneron Pharmaceuticals | ||
| Alnylam Pharmaceuticals | Not disclosed | Not disclosed |
| BeOne Medicines | Not disclosed | Not disclosed |
| BioMarin Pharmaceutical | Not disclosed | Not disclosed |
| Biogen | Not disclosed | Not disclosed |
| Jazz Pharmaceuticals | Not disclosed | Not disclosed |
| Merck | Not disclosed | Not disclosed |
| Neurocrine Biosciences | Not disclosed | Not disclosed |
| Sarepta Therapeutics | Not disclosed | Not disclosed |
| Vertex Pharmaceuticals | Not disclosed | Not disclosed |
12 companies
Changes by year
FY2024 (Dec) proxy
- AddedNeurocrinepay peer group
- AddedSareptapay peer group
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.